Model-based optimization approaches for precision medicine: A case study in presynaptic dopamine overactivity
Open Access
- 14 June 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6), e0179575
- https://doi.org/10.1371/journal.pone.0179575
Abstract
Precision medicine considers an individual’s unique physiological characteristics as strongly influential in disease vulnerability and in response to specific therapies. Predicting an individual’s susceptibility to developing an illness, making an accurate diagnosis, maximizing therapeutic effects, and minimizing adverse effects for treatment are essential in precision medicine. We introduced model-based precision medicine optimization approaches, including pathogenesis, biomarker detection, and drug target discovery, for treating presynaptic dopamine overactivity. Three classes of one-hit and two-hit enzyme defects were detected as the causes of disease states by the optimization approach of pathogenesis. The cluster analysis and support vector machine was used to detect optimal biomarkers in order to discriminate the accurate etiology from three classes of disease states. Finally, the fuzzy decision-making method was employed to discover common and specific drug targets for each classified disease state. We observed that more accurate diagnoses achieved higher satisfaction grades and dosed fewer enzyme targets to treat the disease. Furthermore, satisfaction grades for common drugs were lower than for specific ones, but common drugs could simultaneously treat several disease states that had different etiologies.Funding Information
- Ministry of Science and Technology, Taiwan (MOST103-2221-E-194-045-MY3)
- Ministry of Science and Technology, Taiwan (MOST104-2627-B-194-001)
- Ministry of Science and Technology, Taiwan (MOST105-2627-M-194-001)
This publication has 57 references indexed in Scilit:
- Personalized medicine in psychiatry: problems and promisesBMC Medicine, 2013
- Systems Biology, Bioinformatics, and Biomarkers in NeuropsychiatryFrontiers in Neuroscience, 2012
- Plasma Protein Biomarkers for Depression and Schizophrenia by Multi Analyte Profiling of Case-Control CollectionsPLOS ONE, 2010
- Comparative genomics of autism and schizophreniaProceedings of the National Academy of Sciences of the United States of America, 2010
- Identifying quantitative operation principles in metabolic pathways: a systematic method for searching feasible enzyme activity patterns leading to cellular adaptive responsesBMC Bioinformatics, 2009
- Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminalsSynapse, 2009
- Presynaptic Regulation of Dopamine Transmission in SchizophreniaSchizophrenia Bulletin, 2009
- Support Vector Machines and Kernels for Computational BiologyPLoS Computational Biology, 2008
- Computational Systems Analysis of Dopamine MetabolismPLOS ONE, 2008
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001